ProALL BM
Clinical trial completed- Indications
- Acute lymphoblastic leukemia
Company intelligence / Profile preview
Curewize Health has successfully completed a clinical trial of its lead product, ProALL BM, a bone marrow lab test that enables rapid risk stratification and treatment decision-making for ALL patients. The test provides results within 72 hours compared to the 1–3 months required by standard methods. The company is expanding its portfolio to include blood-based monitoring tests and companion diagnostics for solid tumors, leveraging its proprietary microRNA quantification technology[3][6].
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Curewize Health.